GRAIL (NASDAQ:GRAL) Shares Gap Down – Here’s What Happened

Shares of GRAIL, Inc. (NASDAQ:GRAL) gapped down before the market opened on Tuesday . The stock had previously closed at $59.81, but opened at $57.12. GRAIL shares last traded at $59.7410, with a volume of 68,353 shares.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: The stock is getting active trading interest as multiple law firms publicized the August 4, 2026 lead-plaintiff deadline, keeping GRAIL in the spotlight and drawing attention from investors following the sharp prior selloff. Article Title
• Neutral Sentiment: Several firms, including Levi & Korsinsky, Bernstein Liebhard, Rosen, Schall, Pomerantz, Faruqi & Faruqi, Glancy Prongay, and others, reiterated that a securities class action has been filed and that investors who bought shares during the May 13, 2025 to February 19, 2026 period may seek lead-plaintiff status. Article Title
• Negative Sentiment: The underlying allegation remains that GRAIL allegedly withheld detailed NHS-Galleri trial data and misled investors, which could raise legal risk, pressuring sentiment even though no operational update was reported. Article Title

Analyst Ratings Changes

Several brokerages have weighed in on GRAL. The Goldman Sachs Group began coverage on shares of GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 price objective for the company. Piper Sandler raised their price objective on shares of GRAIL from $54.00 to $56.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Tuesday, April 21st. Morgan Stanley decreased their price objective on shares of GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Finally, Mizuho began coverage on shares of GRAIL in a report on Friday, April 10th. They set a “neutral” rating and a $58.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $67.00.

GRAIL Stock Performance

The company’s fifty day moving average price is $58.55 and its 200 day moving average price is $73.24. The firm has a market capitalization of $2.55 billion, a price-to-earnings ratio of -5.73 and a beta of 3.15.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, beating the consensus estimate of ($2.76) by $0.47. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. The business had revenue of $40.79 million during the quarter, compared to analyst estimates of $39.16 million. As a group, sell-side analysts expect that GRAIL, Inc. will post -10.99 earnings per share for the current year.

Insider Buying and Selling at GRAIL

In related news, CFO Aaron Freidin sold 45,806 shares of GRAIL stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $2,286,635.52. Following the sale, the chief financial officer directly owned 260,669 shares in the company, valued at $13,012,596.48. This trade represents a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert P. Ragusa sold 123,502 shares of GRAIL stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the completion of the sale, the chief executive officer owned 518,582 shares in the company, valued at approximately $25,887,613.44. This represents a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 232,464 shares of company stock valued at $11,621,242. Corporate insiders own 1.83% of the company’s stock.

Institutional Trading of GRAIL

Several hedge funds have recently bought and sold shares of the company. Farallon Capital Management LLC lifted its position in GRAIL by 73.7% in the 4th quarter. Farallon Capital Management LLC now owns 2,342,684 shares of the company’s stock valued at $200,510,000 after purchasing an additional 993,684 shares during the last quarter. Baker BROS. Advisors LP lifted its position in GRAIL by 27.9% in the 4th quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock valued at $178,484,000 after purchasing an additional 455,208 shares during the last quarter. Vanguard Group Inc. lifted its position in GRAIL by 9.0% in the 4th quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock valued at $169,535,000 after purchasing an additional 163,790 shares during the last quarter. State Street Corp lifted its position in GRAIL by 38.8% in the 4th quarter. State Street Corp now owns 1,827,523 shares of the company’s stock valued at $156,418,000 after purchasing an additional 510,546 shares during the last quarter. Finally, Morgan Stanley lifted its position in GRAIL by 63.8% in the 4th quarter. Morgan Stanley now owns 1,511,687 shares of the company’s stock valued at $129,385,000 after purchasing an additional 588,647 shares during the last quarter.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.